BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Amicus Therapeutics for approximately $4.8 billion in an all-cash transaction. The agreement has been approved by the Boards of Directors of both companies. The transaction is expected to close in 2Q26, subject to customary closing conditions. “Amicus, like BioMarin, has been dedicated to transforming care for patients with rare diseases, developing and bringing to market therapies for individuals living wit...